103 related articles for article (PubMed ID: 26528957)
21. Docetaxel chemotherapy for Chinese patients with castrate-resistant prostate cancer.
Cheung FY; Leung KC; Ngan RK
Hong Kong Med J; 2013 Jun; 19(3):237-41. PubMed ID: 23568936
[TBL] [Abstract][Full Text] [Related]
22. Analysis of docetaxel therapy in elderly (≥70 years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study.
Gerritse FL; Meulenbeld HJ; Roodhart JM; van der Velden AM; Blaisse RJ; Smilde TJ; Erjavec Z; de Wit R; Los M;
Eur J Cancer; 2013 Oct; 49(15):3176-83. PubMed ID: 23849828
[TBL] [Abstract][Full Text] [Related]
23. Docetaxel based chemotherapy in the treatment of patients with castration resistant prostate cancer.
Mangir N; Türkeri L
Actas Urol Esp; 2014 Oct; 38(8):515-22. PubMed ID: 24646918
[TBL] [Abstract][Full Text] [Related]
24. Treatment outcome of docetaxel plus prednisolone for metastatic castration-resistant prostate cancer in Korea.
Cho IC; Joung JY; Seo HK; Chung J; Park WS; Lee KH
J Cancer Res Ther; 2014; 10(2):251-7. PubMed ID: 25022374
[TBL] [Abstract][Full Text] [Related]
25. CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
Wissing MD; Coenen JL; van den Berg P; Westgeest HM; van den Eertwegh AJ; van Oort IM; Bos MM; Bergman AM; Hamberg P; Ten Tije AJ; Los M; Lolkema MP; de Wit R; Gelderblom H
Int J Cancer; 2015 Mar; 136(6):E760-72. PubMed ID: 25242736
[TBL] [Abstract][Full Text] [Related]
26. Phase I safety and pharmacodynamic of inecalcitol, a novel VDR agonist with docetaxel in metastatic castration-resistant prostate cancer patients.
Medioni J; Deplanque G; Ferrero JM; Maurina T; Rodier JM; Raymond E; Allyon J; Maruani G; Houillier P; Mackenzie S; Renaux S; Dufour-Lamartinie JF; Elaidi R; Lerest C; Oudard S
Clin Cancer Res; 2014 Sep; 20(17):4471-7. PubMed ID: 25013124
[TBL] [Abstract][Full Text] [Related]
27. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
[TBL] [Abstract][Full Text] [Related]
28. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.
Armstrong AJ; Creel P; Turnbull J; Moore C; Jaffe TA; Haley S; Petros W; Yenser S; Gockerman JP; Sleep D; Hurwitz H; George DJ
Clin Cancer Res; 2008 Oct; 14(19):6270-6. PubMed ID: 18829508
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of metronomic oral cyclophosphamide with low dose dexamethasone and celecoxib in metastatic castration-resistant prostate cancer.
Jeong Y; Lee JL
Asia Pac J Clin Oncol; 2017 Jun; 13(3):204-211. PubMed ID: 27521286
[TBL] [Abstract][Full Text] [Related]
30. Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients.
Buonerba C; Federico P; D'Aniello C; Rescigno P; Cavaliere C; Puglia L; Ferro M; Altieri V; Perdonà S; De Placido S; Di Lorenzo G
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1455-61. PubMed ID: 21365219
[TBL] [Abstract][Full Text] [Related]
31. Docetaxel-prednisolone combination therapy for Japanese patients with hormone-refractory prostate cancer: a single institution experience.
Miura N; Numata K; Kusuhara Y; Shirato A; Hashine K; Sumiyoshi Y
Jpn J Clin Oncol; 2010 Nov; 40(11):1092-8. PubMed ID: 20587613
[TBL] [Abstract][Full Text] [Related]
32. Role of sorafenib in overcoming resistance of chemotherapy-failure castration-resistant prostate cancer.
Meyer A; Cygan P; Tolzien K; Galvez AG; Bitran JD; Lestingi TM; Nabhan C
Clin Genitourin Cancer; 2014 Apr; 12(2):100-5. PubMed ID: 24169494
[TBL] [Abstract][Full Text] [Related]
33. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF.
Aggarwal RR; Beer TM; Weinberg VK; Higano C; Taplin ME; Ryan CJ; Lin AM; Alumkal J; Graff JN; Nordquist LT; Herrera I; Small EJ
Clin Genitourin Cancer; 2015 Jun; 13(3):e191-8. PubMed ID: 25557266
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer.
Leibowitz-Amit R; Templeton AJ; Alibhai SM; Knox JJ; Sridhar SS; Tannock IF; Joshua AM
J Geriatr Oncol; 2015 Jan; 6(1):23-8. PubMed ID: 25301537
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and toxicity of molecular targeted therapies in combination with docetaxel for metastatic castration-resistant prostate cancer: a meta-analysis of phase III randomized controlled trials.
Qi WX; Fu S; Zhang Q; Guo XM
J Chemother; 2015 Jun; 27(3):181-7. PubMed ID: 25492160
[TBL] [Abstract][Full Text] [Related]
36. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
[TBL] [Abstract][Full Text] [Related]
37. Safety and antitumor efficacy of (153)Sm-EDTMP and docetaxel administered sequentially to patients with metastatic castration-resistant prostate cancer.
Borsò E; Boni G; Pastina I; Lorenzoni A; Cianci C; Federici F; Mazzarri S; Orlandini C; Francesca F; Selli C; Ricci S; Rubello D; Mariani G
Nucl Med Commun; 2014 Jan; 35(1):88-94. PubMed ID: 24157942
[TBL] [Abstract][Full Text] [Related]
38. Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer.
Heck MM; Thalgott M; Retz M; Wolf P; Maurer T; Nawroth R; Hatzichristodoulou G; Gschwend JE; Kübler H
BJU Int; 2012 Dec; 110(11 Pt B):E635-40. PubMed ID: 22889368
[TBL] [Abstract][Full Text] [Related]
39. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
Meulenbeld HJ; van Werkhoven ED; Coenen JL; Creemers GJ; Loosveld OJ; de Jong PC; Ten Tije AJ; Fosså SD; Polee M; Gerritsen W; Dalesio O; de Wit R
Eur J Cancer; 2012 Nov; 48(16):2993-3000. PubMed ID: 22677260
[TBL] [Abstract][Full Text] [Related]
40. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
Nelius T; Klatte T; Yap R; Kalinski T; Röpke A; Filleur S; Allhoff EP
BJU Int; 2006 Sep; 98(3):580-5. PubMed ID: 16925757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
